Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study

CONCLUSION: In this retrospective series of KIT exon 9-mutated GIST patients treated with adjuvant imatinib, a daily dose of 800 mg versus 400 mg did not show better results in terms of survival outcomes. Prospective evaluation of the more appropriate adjuvant treatment in this setting is warranted.PMID:34615721 | DOI:10.1158/1078-0432.CCR-21-1665

Source: Clinical Cancer Research - October 7, 2021 Category: Cancer & Oncology Authors: Bruno Vincenzi Andrea Napolitano Marta Fiocco Olivier Mir Piotr Rutkowski Jean-Yves Blay Peter Reichardt Heikki Joensuu Elena Fumagalli Spyridon Gennatas Nadia Hindi Margherita Nannini Mariella Spalato Ceruso Antoine Italiano Giovanni Grignani Antonella B Source Type: research